It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Complex conformational dynamics are essential for function of the dimeric molecular chaperone heat shock protein 90 (Hsp90), including transient, ATP-biased N-domain dimerization that is necessary to attain ATPase competence. The intrinsic, but weak, ATP hydrolyzing activity of human Hsp90 is markedly enhanced by the co-chaperone Aha1. However, the cellular concentration of Aha1 is substoichiometric relative to Hsp90. Here we report that initial recruitment of this cochaperone to Hsp90 is markedly enhanced by phosphorylation of a highly conserved tyrosine (Y313 in Hsp90α) in the Hsp90 middle domain. Importantly, phosphomimetic mutation of Y313 promotes formation of a transient complex in which both N- and C-domains of Aha1 bind to distinct surfaces of the middle domains of opposing Hsp90 protomers prior to ATP-directed N-domain dimerization. Thus, Y313 represents a phosphorylation-sensitive conformational switch, engaged early after client loading, that affects both local and long-range conformational dynamics to facilitate initial recruitment of Aha1 to Hsp90.
Phosphorylation of Tyr313 in Hsp90 enhances the binding to its activator Aha1, but the underlying mechanism is unknown. Here, the authors study the structural consequences of Tyr313 phosphorylation, showing that it serves as a conformational switch in Hsp90 that enables Aha1 recruitment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 National Cancer Institute, Urologic Oncology Branch, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
2 University of Washington School of Medicine, Department of Genome Sciences, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
3 University of Heidelberg, Center for Molecular Biology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
4 National Cancer Institute, Urologic Oncology Branch, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075); Beijing 302 Hospital, Center for Therapeutic Research of Hepatocarcinoma, Beijing, China (GRID:grid.413135.1) (ISNI:0000 0004 1764 3045)
5 University of South Florida, Department of Chemistry, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
6 National Cancer Institute, Developmental Therapeutics Branch, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
7 University of Sussex, Genome and Damage Stability Center, Brighton, UK (GRID:grid.12082.39) (ISNI:0000 0004 1936 7590)